DOI . ORG {}

Matching Content Categories {📚}

• Education
• Science
• Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

sorafenib, article, pubmed, google, scholar, hepatocellular, carcinoma, cas, patients, advanced, study, oncol, cancer, phase, clin, gideon, trial, analysis, treatment, clinical, hcc, safety, liver, iii, hepatol, randomized, central, abstract, results, access, practice, chen, suppl, efficacy, kudo, content, therapeutic, tumor, res, cheng, privacy, cookies, function, information, search, oncology, review, keating, unresectable, therapy,

Topics {✒️}

targets raf/mek/erk pathway month download article/chapter /html/products/pi/nexavar_pi raf/mek/erk pathway abou-alfa gk hand-foot skin reactions tyrosine kinases vegfr/pdgfr open-label study major kinase-independent target ketoconazole-mediated cyp3a inhibition sorafenib relieves cell-intrinsic pro-apoptotic sorafenib signaling di costanzo related subjects llovet jm full article pdf open-label privacy choices/manage cookies augment antitumor immunity asia-pacific region phase iii study dual-action inhibitor intermediate stage hcc phase iii trial field-practice study phase iii failure liver function assessment cheng a cell-extrinsic inhibitions phase ii study sorafenib asia-pacific randomized clinical trial cell death dis european economic area international observational study patient surveillance study phase iv study murine hepatocytes depends european patient subset advanced hepatocellular carcinoma phase iii randomised randomized controlled trial sunitinib versus sorafenib brivanib versus sorafenib linifanib versus sorafenib doxorubicin versus sorafenib advanced hepatocellular cancer systemic agent approved manage adverse effects bayer healthcare pharmaceuticals

Questions {❓}

• Learning from 7 years of experience with sorafenib in advanced HCC: sorafenib better than sorafenib?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Sorafenib: A Review in Hepatocellular Carcinoma
         description:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall survival (OS) and time to radiological progression (TTP) with sorafenib 400 mg twice daily than with placebo, with no significant between-group difference in the median time to symptomatic progression (TTSP). Subsequent results from real-world studies such as GIDEON also support the use of sorafenib in HCC, including in carefully selected CP class B patients, although the median OS achieved in these patients appears relatively short. Sorafenib has a well characterized tolerability and safety profile, with strategies available to prevent and manage adverse effects such as hand-foot skin reactions. In conclusion, sorafenib remains an important option for the treatment of HCC.
         datePublished:2017-03-15T00:00:00Z
         dateModified:2017-03-15T00:00:00Z
         pageStart:243
         pageEnd:253
         sameAs:https://doi.org/10.1007/s11523-017-0484-7
         keywords:
            Overall Survival
            Sorafenib
            Tace
            Median Overall Survival
            National Comprehensive Cancer Network
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figa_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figb_HTML.gif
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gillian M. Keating
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Sorafenib: A Review in Hepatocellular Carcinoma
      description:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall survival (OS) and time to radiological progression (TTP) with sorafenib 400 mg twice daily than with placebo, with no significant between-group difference in the median time to symptomatic progression (TTSP). Subsequent results from real-world studies such as GIDEON also support the use of sorafenib in HCC, including in carefully selected CP class B patients, although the median OS achieved in these patients appears relatively short. Sorafenib has a well characterized tolerability and safety profile, with strategies available to prevent and manage adverse effects such as hand-foot skin reactions. In conclusion, sorafenib remains an important option for the treatment of HCC.
      datePublished:2017-03-15T00:00:00Z
      dateModified:2017-03-15T00:00:00Z
      pageStart:243
      pageEnd:253
      sameAs:https://doi.org/10.1007/s11523-017-0484-7
      keywords:
         Overall Survival
         Sorafenib
         Tace
         Median Overall Survival
         National Comprehensive Cancer Network
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figa_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-017-0484-7/MediaObjects/11523_2017_484_Figb_HTML.gif
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gillian M. Keating
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:12
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gillian M. Keating
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Springer, Auckland, New Zealand
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(246)

• How much does https://link.springer.com/privacystatement rake in every month?
• Earnings of https://link.springer.com/article/10.1007/s11523-017-0484-7/#main
• What is the earnings of https://link.springer.com?
• What's the financial gain of https://idp.springer.com/auth/personal/springernature?redirect_uri=https://link.springer.com/article/10.1007/s11523-017-0484-7?
• Earnings of https://link.springer.com/article/10.1007/s11523-017-0484-7/#eds-c-header-nav
• What's the financial gain of https://link.springer.com/journals/?
• What's the financial outcome of https://www.springernature.com/gp/authors?
• https://link.springernature.com/home/'s revenue stream
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/#eds-c-header-popup-search pull in?
• Discover the revenue of https://order.springer.com/public/cart
• Explore the financials of https://link.springer.com/article/10.1007/s11523-017-0484-7/
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/journal/11523 earn?
• How much revenue does https://link.springer.com/article/10.1007/s11523-017-0484-7/#citeas produce monthly?
• What is the monthly revenue of https://link.springer.com/article/10.1007/s11523-017-0484-7/journal/11523/aims-and-scope?
• What's the financial gain of https://www.editorialmanager.com/targ?
• See how much https://link.springer.com/article/10.1007/s11523-017-0484-7/#auth-Gillian_M_-Keating-Aff1 makes per month
• Discover the revenue of https://link.springer.com/article/10.1007/s11523-017-0484-7/#Aff1
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/article/10.1007/s11523-017-0484-7/metrics pull in monthly?
• How much money does https://wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11523-017-0484-7 make?
• What's the financial intake of https://link.springer.com/product/springer-plus?
• How much does https://www.springernature.com/gp/librarians/licensing/agc/journals rake in every month?
• How much revenue does https://link.springer.com/10.1038/s41392-020-0187-x?fromPaywallRec=true produce monthly?
• How much income does https://link.springer.com/10.1007/s12072-016-9774-x?fromPaywallRec=true have?
• What's https://link.springer.com/10.1186/s12885-018-4144-9?fromPaywallRec=true's gross income?
• What's the profit of https://link.springer.com/article/10.1007/s11523-017-0484-7/subjects/chemotherapy?
• https://link.springer.com/article/10.1007/s11523-017-0484-7/subjects/liver-cancer's total income per month
• What's the income of https://link.springer.com/article/10.1007/s11523-017-0484-7/subjects/hepatitis-c?
• How much revenue does https://link.springer.com/article/10.1007/s11523-017-0484-7/subjects/molecularly-targeted-therapy produce monthly?
• https://link.springer.com/article/10.1007/s11523-017-0484-7/subjects/targeted-therapies's revenue stream
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/subjects/hepatocellular-carcinoma make?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23560372
• Get to know http://scholar.google.com/scholar_lookup?&title=Selection%20and%20management%20of%20hepatocellular%20carcinoma%20patients%20with%20sorafenib%3A%20recommendations%20and%20opinions%20from%20an%20Italian%20liver%20unit&journal=Future%20Oncol&doi=10.2217%2Ffon.12.208&volume=9&issue=4&pages=485-91&publication_year=2013&author=D%E2%80%99Angelo%2CS&author=Secondulfo%2CM&author=Cristofano%2CR's earnings
• Profit of http://www.nccn.org/
• How much revenue does http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf generate?
• What's the income generated by http://www.ema.europa.eu/ each month?
• How much income does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD2sXmt1SnsL4%3D have?
• How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16757355 have monthly?
• See how much http://scholar.google.com/scholar_lookup?&title=Sorafenib%20%28BAY%2043%E2%80%939006%2C%20Nexavar%C2%AE%29%2C%20a%20dual-action%20inhibitor%20that%20targets%20RAF%2FMEK%2FERK%20pathway%20in%20tumor%20cells%20and%20tyrosine%20kinases%20VEGFR%2FPDGFR%20in%20tumor%20vasculature&journal=Methods%20Enzymol&doi=10.1016%2FS0076-6879%2805%2907047-3&volume=407&pages=597-612&publication_year=2006&author=Adnane%2CL&author=Trail%2CPA&author=Taylor%2CI makes per month
• What's https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD28XhtVajsbbM's gross income?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17016424 rake in every month?
• How much money does http://scholar.google.com/scholar_lookup?&title=Discovery%20and%20development%20of%20sorafenib%3A%20a%20multikinase%20inhibitor%20for%20treating%20cancer&journal=Nat%20Rev%20Drug%20Discov&doi=10.1038%2Fnrd2130&volume=5&issue=10&pages=835-44&publication_year=2006&author=Wilhelm%2CS&author=Carter%2CC&author=Lynch%2CM make?
• Discover the revenue of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD2cXotFalsbk%3D
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15466206 net monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=BAY%2043%E2%80%939006%20exhibits%20broad%20spectrum%20oral%20antitumor%20activity%20and%20targets%20the%20RAF%2FMEK%2FERK%20pathway%20and%20receptor%20tyrosine%20kinases%20involved%20in%20tumor%20progression%20and%20angiogenesis&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-04-1443&volume=64&issue=19&pages=7099-109&publication_year=2004&author=Wilhelm%2CSM&author=Carter%2CC&author=Tang%2CL pull in?
• Get to know https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD28Xhtlagu73F's earnings
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17178882 generate?
• How much money does http://scholar.google.com/scholar_lookup?&title=Sorafenib%20blocks%20the%20RAF%2FMEK%2FERK%20pathway%2C%20inhibits%20tumor%20angiogenesis%2C%20and%20induces%20tumor%20cell%20apoptosis%20in%20hepatocellular%20carcinoma%20model%20PLC%2FPRF%2F5&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-06-1377&volume=66&issue=24&pages=11851-8&publication_year=2006&author=Liu%2CL&author=Cao%2CY&author=Chen%2CC make?
• What's the income of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3sXhvFSksrbL?
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24081937 make?
• http://scholar.google.com/scholar_lookup?&title=Sunitinib%20versus%20sorafenib%20in%20advanced%20hepatocellular%20cancer%3A%20results%20of%20a%20randomized%20phase%20III%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2012.45.8372&volume=31&issue=32&pages=4067-75&publication_year=2013&author=Cheng%2CA-L&author=Kang%2CY-K&author=Lin%2CD-Y's revenue stream
• https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3sXhs12mt7%2FN's revenue stream
• How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23980084 earning monthly?
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Brivanib%20versus%20sorafenib%20as%20first-line%20therapy%20in%20patients%20with%20unresectable%2C%20advanced%20hepatocellular%20carcinoma%3A%20results%20from%20the%20randomized%20phase%20III%20BRISK-FL%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2012.48.4410&volume=31&issue=28&pages=3517-24&publication_year=2013&author=Johnson%2CPJ&author=Qin%2CS&author=Park%2CJ-W is on a monthly basis
• What's the monthly money flow for https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXit1Chu7c%3D?
• What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25488963?
• How much does http://scholar.google.com/scholar_lookup?&title=Linifanib%20versus%20sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%3A%20results%20of%20a%20randomized%20phase%20III%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2013.54.3298&volume=33&issue=2&pages=172-9&publication_year=2015&author=Cainap%2CC&author=Qin%2CS&author=Huang%2CW-T pull in?
• What's the financial intake of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28XhtlOnu7fM?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27082062 pull in?
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Randomized%2C%20open-label%20phase%202%20study%20comparing%20frontline%20dovitinib%20versus%20sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma&journal=Hepatology&doi=10.1002%2Fhep.28600&volume=64&issue=3&pages=774-84&publication_year=2016&author=Cheng%2CA-L&author=Thongprasert%2CS&author=Lim%2CHY
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXktlCntrw%3D make?
• Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25547503 is on a monthly basis
• Get to know http://scholar.google.com/scholar_lookup?&title=SEARCH%3A%20a%20phase%20III%2C%20randomized%2C%20double-blind%2C%20placebo-controlled%20trial%20of%20sorafenib%20plus%20erlotinib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2013.53.7746&volume=33&issue=6&pages=559-66&publication_year=2015&author=Zhu%2CAX&author=Rosmorduc%2CO&author=Evans%2CTRJ's earnings
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27508178
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918267's financial summary
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Sorafenib%20in%20advanced%20hepatocellular%20carcinoma%3A%20current%20status%20and%20future%20perspectives&journal=J%20Hepatocell%20Carcinoma&volume=1&pages=85-99&publication_year=2014&author=Hsu%2CC-H&author=Shen%2CY-C&author=Shao%2CY-Y
• Profit of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtl2rsLrO
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20884624's revenue stream
• How much income does http://scholar.google.com/scholar_lookup?&title=Sorafenib%20overcomes%20TRAIL%20resistance%20of%20hepatocellular%20carcinoma%20cells%20through%20the%20inhibition%20of%20STAT3&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-09-3389&volume=16&issue=21&pages=5189-99&publication_year=2010&author=Chen%2CK-F&author=Tai%2CW-T&author=Liu%2CT-H have?
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtleqsrbE gross monthly?
• How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21354226 making per month?
• Profit of http://scholar.google.com/scholar_lookup?&title=Signal%20transducer%20and%20activator%20of%20transcription%203%20is%20a%20major%20kinase-independent%20target%20of%20sorafenib%20in%20hepatocellular%20carcinoma&journal=J%20Hepatol&doi=10.1016%2Fj.jhep.2011.01.047&volume=55&issue=5&pages=1041-8&publication_year=2011&author=Tai%2CW-T&author=Cheng%2CA-L&author=Shiau%2CC-W
• What are the earnings of https://link.springer.com/doi/10.1007/s11523-016-0452-7?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27510230 earn?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Targeting%20multiple%20oncogenic%20pathways%20for%20the%20treatment%20of%20hepatocellular%20carcinoma&journal=Target%20Oncol&doi=10.1007%2Fs11523-016-0452-7&volume=12&issue=1&pages=1-10&publication_year=2017&author=Swamy%2CSG&author=Kameshwar%2CVH&author=Shubha%2CPB
• What are the total earnings of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2cXhsl2mt7s%3D?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24481444 income
• What's the income generated by http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040679 each month?
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Pro-apoptotic%20sorafenib%20signaling%20in%20murine%20hepatocytes%20depends%20on%20malignancy%20and%20is%20associated%20with%20PUMA%20expression%20in%20vitro%20and%20in%20vivo&journal=Cell%20Death%20Dis&doi=10.1038%2Fcddis.2013.557&volume=5&publication_year=2014&author=Sonntag%2CR&author=Gassler%2CN&author=Bangen%2CJ-M?
• What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23818246?
• http://scholar.google.com/scholar_lookup?&title=Sorafenib%20relieves%20cell-intrinsic%20and%20cell-extrinsic%20inhibitions%20of%20effector%20T%20cells%20in%20tumor%20microenvironment%20to%20augment%20antitumor%20immunity&journal=Int%20J%20Cancer&doi=10.1002%2Fijc.28362&volume=134&issue=2&pages=319-31&publication_year=2014&author=Chen%2CM-L&author=Yan%2CB-S&author=Lu%2CW-C income
• What are the earnings of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3MXjvFKgtLo%3D?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21321535 bring in?
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711234 have monthly?
• Income figures for http://scholar.google.com/scholar_lookup?&title=Kinase%20inhibitor%20sorafenib%20modulates%20immunosuppressive%20cell%20populations%20in%20a%20murine%20liver%20cancer%20model&journal=Lab%20Investig&doi=10.1038%2Flabinvest.2010.205&volume=91&issue=4&pages=598-608&publication_year=2011&author=Cao%2CM&author=Xu%2CY&author=Youn%2CJ-I
• What's the income generated by https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFOkt7rN each month?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26170167 pull in monthly?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Potential%20molecular%2C%20cellular%20and%20microenvironmental%20mechanism%20of%20sorafenib%20resistance%20in%20hepatocellular%20carcinoma&journal=Cancer%20Lett&doi=10.1016%2Fj.canlet.2015.06.019&volume=367&issue=1&pages=1-11&publication_year=2015&author=Chen%2CJ&author=Jin%2CR&author=Zhao%2CJ make?
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26488287 have?
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Molecular%20mechanism%20and%20prediction%20of%20sorafenib%20chemoresistance%20in%20human%20hepatocellular%20carcinoma&journal=Dig%20Dis&doi=10.1159%2F000439102&volume=33&issue=6&pages=771-9&publication_year=2015&author=Nishida%2CN&author=Kitano%2CM&author=Sakurai%2CT
• How profitable is https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD2MXit1Ggu7c%3D?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15613696 pull in?
• How much does http://scholar.google.com/scholar_lookup?&title=Phase%20I%20clinical%20and%20pharmacokinetic%20study%20of%20the%20novel%20Raf%20kinase%20and%20vascular%20endothelial%20growth%20factor%20receptor%20inhibitor%20BAY%2043%E2%80%939006%20in%20patients%20with%20advanced%20refractory%20solid%20tumors&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2005.06.124&volume=23&issue=5&pages=965-72&publication_year=2005&author=Strumberg%2CD&author=Richly%2CH&author=Hilger%2CRA net monthly?
• Explore the financials of https://link.springer.com/doi/10.1007/s00280-005-0068-6
• How much profit is https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD28Xjs1KktLk%3D making per month?
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16133532
• How much does http://scholar.google.com/scholar_lookup?&title=Lack%20of%20effect%20of%20ketoconazole-mediated%20CYP3A%20inhibition%20on%20sorafenib%20clinical%20pharmacokinetics&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs00280-005-0068-6&volume=57&issue=5&pages=685-92&publication_year=2006&author=Lathia%2CC&author=Lettieri%2CJ&author=Cihon%2CF pull in?
• What's the monthly money flow for https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD28XhtVGju7jE?
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16908937
• How profitable is http://scholar.google.com/scholar_lookup?&title=Phase%20II%20study%20of%20sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2005.01.3441&volume=24&issue=26&pages=4293-300&publication_year=2006&author=Abou-Alfa%2CGK&author=Schwartz%2CL&author=Ricci%2CS?
• How much revenue does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD1cXovFWjsL8%3D produce monthly?
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18650514 have?
• How much does http://scholar.google.com/scholar_lookup?&title=Sorafenib%20in%20advanced%20hepatocellular%20carcinoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa0708857&volume=359&issue=4&pages=378-90&publication_year=2008&author=Llovet%2CJM&author=Ricci%2CS&author=Mazzaferro%2CV bring in each month?
• What's https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BD1cXhsFChtbnM's gross income?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19095497's revenue stream
• How much profit does http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20sorafenib%20in%20patients%20in%20the%20Asia-Pacific%20region%20with%20advanced%20hepatocellular%20carcinoma%3A%20a%20phase%20III%20randomised%2C%20double-blind%2C%20placebo-controlled%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2808%2970285-7&volume=10&issue=1&pages=25-34&publication_year=2009&author=Cheng%2CA-L&author=Kang%2CY-K&author=Chen%2CZ make?
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC38XhtlOgsb%2FE gross monthly?
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22727733's earnings
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%3A%20subanalyses%20of%20a%20phase%20III%20trial&journal=J%20Hepatol&doi=10.1016%2Fj.jhep.2012.06.014&volume=57&issue=4&pages=821-9&publication_year=2012&author=Bruix%2CJ&author=Raoul%2CJ-L&author=Sherman%2CM
• How profitable is https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC38XosFWhuro%3D?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22240282
• Financial intake of http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20according%20to%20baseline%20status%3A%20subset%20analyses%20of%20the%20phase%20III%20Sorafenib%20Asia-Pacific%20trial&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2011.12.006&volume=48&issue=10&pages=1452-65&publication_year=2012&author=Cheng%2CA-L&author=Guan%2CZ&author=Chen%2CZ
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Prognostic%20factors%20and%20predictors%20of%20response%20to%20sorafenib%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20%28HCC%29%3A%20pooled%20analysis%20of%20randomized%20clinical%20trials%20%5Babstract%20no.%20O-140%20plus%20slide%20presentation%5D&journal=Hepatol%20Int&volume=10&issue=Suppl%201&pages=S57-8&publication_year=2016&author=Bruix%2CJ&author=Cheng%2CA-L&author=Meinhardt%2CG?
• What's the profit of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC38XlvFGgtL8%3D?
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22245896?
• Find out how much http://scholar.google.com/scholar_lookup?&title=Relationship%20between%20baseline%20hepatic%20status%20and%20outcome%2C%20and%20effect%20of%20sorafenib%20on%20liver%20function%3A%20SHARP%20trial%20subanalyses&journal=J%20Hepatol&doi=10.1016%2Fj.jhep.2011.12.009&volume=56&issue=5&pages=1080-8&publication_year=2012&author=Raoul%2CJ-L&author=Bruix%2CJ&author=Greten%2CTF earns monthly
• How much profit does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:STN:280:DC%2BC3s%2FivF2nsA%3D%3D make?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23041587 generate?
• http://scholar.google.com/scholar_lookup?&title=Sorafenib%20in%20patients%20with%20Child-Pugh%20class%20A%20and%20B%20advanced%20hepatocellular%20carcinoma%3A%20a%20prospective%20feasibility%20analysis&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmds343&volume=24&issue=2&pages=406-11&publication_year=2013&author=Pressiani%2CT&author=Boni%2CC&author=Rimassa%2CL's revenue stream
• What's the profit of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVCrtrrL?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26471348
• What is the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123720?
• See how much http://scholar.google.com/scholar_lookup?&title=Sorafenib%20for%20the%20treatment%20of%20advanced%20hepatocellular%20carcinoma%20with%20extrahepatic%20metastasis%3A%20a%20prospective%20multicenter%20cohort%20study&journal=Cancer%20Med&doi=10.1002%2Fcam4.548&volume=4&issue=12&pages=1836-43&publication_year=2015&author=Nakano%2CM&author=Tanaka%2CM&author=Kuromatsu%2CR makes per month
• https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28XhtlyqtrzJ's financial summary
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27469901?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Observational%20registry%20of%20sorafenib%20use%20in%20clinical%20practice%20across%20Child-Pugh%20subgroups%3A%20the%20GIDEON%20study&journal=J%20Hepatol&doi=10.1016%2Fj.jhep.2016.07.020&volume=65&issue=6&pages=1140-7&publication_year=2016&author=Marrero%2CJA&author=Kudo%2CM&author=Venook%2CAP generate?
• Find out how much https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:STN:280:DC%2BC38fms1emsA%3D%3D earns monthly
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22698419 rake in every month?
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=First%20interim%20analysis%20of%20the%20GIDEON%20%28Global%20Investigation%20of%20therapeutic%20DEcisions%20in%20hepatocellular%20carcinoma%20and%20Of%20its%20treatment%20with%20sorafeNib%29%20non-interventional%20study&journal=Int%20J%20Clin%20Pract&doi=10.1111%2Fj.1742-1241.2012.02940.x&volume=66&issue=7&pages=675-83&publication_year=2012&author=Lencioni%2CR&author=Kudo%2CM&author=Ye%2CS-L have monthly?
• What's the monthly income of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2cXmslyjt7s%3D?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24283303 generate monthly?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=GIDEON%20%28Global%20Investigation%20of%20therapeutic%20DEcisions%20in%20hepatocellular%20carcinoma%20and%20Of%20its%20treatment%20with%20sorafeNib%29%3A%20second%20interim%20analysis&journal=Int%20J%20Clin%20Pract&doi=10.1111%2Fijcp.12352&volume=68&issue=5&pages=609-17&publication_year=2014&author=Lencioni%2CR&author=Kudo%2CM&author=Ye%2CS-L?
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28XhtFCktb7P bring in each month?
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26901163's earnings
• How much income does http://scholar.google.com/scholar_lookup?&title=Regional%20differences%20in%20sorafenib-treated%20patients%20with%20hepatocellular%20carcinoma%3A%20GIDEON%20observational%20study&journal=Liver%20Int&doi=10.1111%2Fliv.13096&volume=36&issue=8&pages=1196-205&publication_year=2016&author=Kudo%2CM&author=Lencioni%2CR&author=Marrero%2CJA have?
• Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26744927 is on a monthly basis
• How much does http://scholar.google.com/scholar_lookup?&title=TACE%20treatment%20in%20patients%20with%20sorafenib-treated%20unresectable%20hepatocellular%20carcinoma%20in%20clinical%20practice%3A%20final%20analysis%20of%20GIDEON&journal=Radiology&doi=10.1148%2Fradiol.2015150667&volume=279&issue=2&pages=630-40&publication_year=2016&author=Geschwind%2CJ-F&author=Kudo%2CM&author=Marrero%2CJA make?
• Discover the revenue of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28XivFGlurw%3D
• What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26989658?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Use%20of%20transarterial%20chemoembolization%20%28TACE%29%20and%20sorafenib%20in%20patients%20with%20unresectable%20hepatocellular%20carcinoma%3A%20US%20regional%20analysis%20of%20the%20GIDEON%20registry&journal=Liver%20Cancer&doi=10.1159%2F000367757&volume=5&issue=1&pages=37-46&publication_year=2016&author=Geschwind%2CJ-FH&author=Gholam%2CPM&author=Goldenberg%2CA produce monthly?
• Find out how much https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsFKktrjJ earns monthly
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26158398?
• How much does http://scholar.google.com/scholar_lookup?&title=Impact%20of%20sorafenib%20dosing%20on%20outcome%20from%20the%20European%20patient%20subset%20of%20the%20GIDEON%20study&journal=Future%20Oncol&doi=10.2217%2Ffon.15.163&volume=11&issue=18&pages=2553-62&publication_year=2015&author=Daniele%2CB&author=Croitoru%2CA&author=Papandreou%2CC make?
• What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25994538?
• How much does http://scholar.google.com/scholar_lookup?&title=Therapeutic%20decisions%20and%20treatment%20with%20sorafenib%20in%20hepatocellular%20carcinoma%3A%20final%20analysis%20of%20GIDEON%20study%20in%20Italy%20%5Bin%20Italian%5D&journal=Recenti%20Prog%20Med&volume=106&issue=5&pages=217-26&publication_year=2015&author=D%E2%80%99Angelo%2CS&author=Germano%2CD&author=Zolfino%2CT make?
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25583146 makes per month
• How much money does http://scholar.google.com/scholar_lookup?&title=Therapeutic%20decisions%20in%20the%20treatment%20of%20hepatocellular%20carcinoma%20and%20patterns%20of%20sorafenib%20use%3A%20results%20of%20the%20international%20observational%20GIDEON%20trial%20in%20Spain%20%5Bin%20Spanish%5D&journal=Gastroenterol%20Hepatol&doi=10.1016%2Fj.gastrohep.2014.11.001&volume=38&issue=4&pages=263-73&publication_year=2015&author=Turnes%2CJ&author=D%C3%ADaz%2CR&author=Hernandez-Guerra%2CM make?
• How much does https://link.springer.com/doi/10.1007/s00535-016-1204-2 bring in each month?
• What's the financial outcome of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28XmslSgsLw%3D?
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27106231?
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121182 have monthly?
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20sorafenib%20in%20Japanese%20patients%20with%20hepatocellular%20carcinoma%20in%20clinical%20practice%3A%20a%20subgroup%20analysis%20of%20GIDEON&journal=J%20Gastroenterol&doi=10.1007%2Fs00535-016-1204-2&volume=51&issue=12&pages=1150-60&publication_year=2016&author=Kudo%2CM&author=Ikeda%2CM&author=Takayama%2CT?
• What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26735891?
• How much income does http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20sorafenib%20therapy%20in%20patients%20with%20hepatocellular%20carcinoma%3A%20final%20outcome%20from%20the%20Chinese%20patient%20subset%20of%20the%20GIDEON%20study&journal=Oncotarget&volume=7&issue=6&pages=6639-48&publication_year=2016&author=Ye%2CS-L&author=Chen%2CX&author=Yang%2CJ have?
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26910470?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080829's financial summary
• Profit of http://scholar.google.com/scholar_lookup?&title=Real-life%20experience%20of%20sorafenib%20treatment%20for%20hepatocellular%20carcinoma%20in%20Korea%3A%20from%20GIDEON%20data&journal=Cancer%20Res%20Treat&doi=10.4143%2Fcrt.2015.278&volume=48&issue=4&pages=1243-52&publication_year=2016&author=Kim%2CDY&author=Kim%2CHJ&author=Han%2CK-H
• Explore the financials of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFCqsLrE
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21898496 bring in each month?
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Field-practice%20study%20of%20sorafenib%20therapy%20for%20hepatocellular%20carcinoma%3A%20a%20prospective%20multicenter%20study%20in%20Italy&journal=Hepatology&doi=10.1002%2Fhep.24644&volume=54&issue=6&pages=2055-63&publication_year=2011&author=Iavarone%2CM&author=Cabibbo%2CG&author=Piscaglia%2CF
• How much money does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3MXhs1SnsrjE generate?
• Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21958438
• How much profit is http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20sorafenib%20in%20hepatocellular%20carcinoma%3A%20the%20impact%20of%20the%20Child-Pugh%20score&journal=Aliment%20Pharmacol%20Ther&doi=10.1111%2Fj.1365-2036.2011.04860.x&volume=34&issue=10&pages=1193-201&publication_year=2011&author=Hollebecque%2CA&author=Cattan%2CS&author=Romano%2CO making per month?
• What's the financial outcome of https://link.springer.com/doi/10.1007/s11523-016-0454-5?
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27503006
• Income figures for http://scholar.google.com/scholar_lookup?&title=Impact%20of%20diabetes%20on%20outcomes%20of%20sorafenib%20therapy%20for%20hepatocellular%20carcinoma&journal=Target%20Oncol&doi=10.1007%2Fs11523-016-0454-5&volume=12&issue=1&pages=61-7&publication_year=2017&author=Costanzo%2CGG&author=Tortora%2CR&author=Morisco%2CF
• How much does https://link.springer.com/doi/10.1007/s00535-016-1173-5 pull in?
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28XjtlOgtL4%3D rake in every month?
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26931117 makes per month
• Learn how profitable http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037148 is on a monthly basis
• How much profit does http://scholar.google.com/scholar_lookup?&title=Safety%20and%20effectiveness%20of%20sorafenib%20in%20Japanese%20patients%20with%20hepatocellular%20carcinoma%20in%20daily%20medical%20practice%3A%20interim%20analysis%20of%20a%20prospective%20postmarketing%20all-patient%20surveillance%20study&journal=J%20Gastroenterol&doi=10.1007%2Fs00535-016-1173-5&volume=51&issue=10&pages=1011-21&publication_year=2016&author=Kaneko%2CS&author=Ikeda%2CK&author=Matsuzaki%2CY generate?
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXpvVCitbk%3D make?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24698672's revenue stream
• http://scholar.google.com/scholar_lookup?&title=Sorafenib%20in%20liver%20function%20impaired%20advanced%20hepatocellular%20carcinoma&journal=Chin%20Med%20Sci%20J&doi=10.1016%2FS1001-9294%2814%2960017-1&volume=29&issue=1&pages=7-14&publication_year=2014&author=Ji%2CY-X&author=Zhang%2CZ-F&author=Lan%2CK-T's revenue stream
• What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22997453?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Hepatocellular%20carcinoma%3A%20ESMO-ESDO%20clinical%20practice%20guidelines%20for%20diagnosis%2C%20treatment%20and%20follow-up&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmds225&volume=23&issue=Suppl%207&pages=vii41-8&publication_year=2012&author=Verslype%2CC&author=Rosmorduc%2CO&author=Rougier%2CP?
• Get to know what's the income of https://link.springer.com/doi/10.1007/s11523-016-0427-8
• Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26996978 is on a monthly basis
• How much does http://scholar.google.com/scholar_lookup?&title=Learning%20from%207%C2%A0years%20of%20experience%20with%20sorafenib%20in%20advanced%20HCC%3A%20sorafenib%20better%20than%20sorafenib%3F&journal=Target%20Oncol&doi=10.1007%2Fs11523-016-0427-8&volume=11&issue=4&pages=565-7&publication_year=2016&author=Faivre%2CS&author=Gramont%2CA&author=Raymond%2CE pull in?
• Get to know what's the income of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28Xit12ks78%3D
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26809111 make?
• Revenue of http://scholar.google.com/scholar_lookup?&title=Sorafenib%20or%20placebo%20plus%20TACE%20with%20doxorubicin-eluting%20beads%20for%20intermediate%20stage%20HCC%3A%20the%20SPACE%20trial&journal=J%20Hepatol&doi=10.1016%2Fj.jhep.2016.01.012&volume=64&issue=5&pages=1090-8&publication_year=2016&author=Lencioni%2CR&author=Llovet%2CJM&author=Han%2CG
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC38XmvVehsbg%3D gross monthly?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22334456 make?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316921?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Transarterial%20chemoembolization%20plus%20sorafenib%3A%20a%20sequential%20therapeutic%20scheme%20for%20HCV-related%20intermediate-stage%20hepatocellular%20carcinoma%3A%20a%20randomized%20clinical%20trial&journal=Oncologist&doi=10.1634%2Ftheoncologist.2011-0313&volume=17&issue=3&pages=359-66&publication_year=2012&author=Sansonno%2CD&author=Lauletta%2CG&author=Russi%2CS
• What's the total monthly financial gain of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtFKit77O?
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21664811 have?
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Phase%20III%20study%20of%20sorafenib%20after%20transarterial%20chemoembolisation%20in%20Japanese%20and%20Korean%20patients%20with%20unresectable%20hepatocellular%20carcinoma&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2011.05.007&volume=47&issue=14&pages=2117-27&publication_year=2011&author=Kudo%2CM&author=Imanaka%2CK&author=Chida%2CN is on a monthly basis
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXpvFahtrs%3D earn?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25667293
• How much does http://scholar.google.com/scholar_lookup?&title=Randomized%20controlled%20trial%20of%20the%20prophylactic%20effect%20of%20urea-based%20cream%20on%20sorafenib-associated%20hand-foot%20skin%20reactions%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2013.52.9651&volume=33&issue=8&pages=894-900&publication_year=2015&author=Ren%2CZ&author=Zhu%2CK&author=Kang%2CH gross monthly?
• Profit of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC38XltVOqsrs%3D
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22354124?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Sorafenib%20dose%20escalation%20in%20the%20treatment%20of%20advanced%20hepatocellular%20carcinoma&journal=Oncology&doi=10.1159%2F000336082&volume=82&issue=2&pages=119-25&publication_year=2012&author=Kim%2CJE&author=Ryoo%2CB-Y&author=Ryu%2CM-H
• What's the total monthly financial gain of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC28XitVajsrrN?
• Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27932229 is on a monthly basis
• How much income is http://scholar.google.com/scholar_lookup?&title=Regorafenib%20for%20patients%20with%20hepatocellular%20carcinoma%20who%20progressed%20on%20sorafenib%20treatment%20%28RESORCE%29%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%203%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2816%2932453-9&volume=389&issue=10064&pages=56-66&publication_year=2017&author=Bruix%2CJ&author=Qin%2CS&author=Merle%2CP earning monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27678348 bring in each month?
• What are the total earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016365?
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Challenges%20of%20advanced%20hepatocellular%20carcinoma&journal=World%20J%20Gastroenterol&doi=10.3748%2Fwjg.v22.i34.7645&volume=22&issue=34&pages=7645-59&publication_year=2016&author=Colagrande%2CS&author=Inghilesi%2CAL&author=Aburas%2CS?
• How much money does https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2cXmtl2msL4%3D generate?
• Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24589894
• Financial intake of http://scholar.google.com/scholar_lookup?&title=Hepatocellular%20carcinoma%3A%20reasons%20for%20phase%20III%20failure%20and%20novel%20perspectives%20on%20trial%20design&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-13-0547&volume=20&issue=8&pages=2072-9&publication_year=2014&author=Llovet%2CJM&author=Hernandez-Gea%2CV
• Profit of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC38XmsFOnur0%3D
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22374331
• Earnings of http://scholar.google.com/scholar_lookup?&title=Plasma%20biomarkers%20as%20predictors%20of%20outcome%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-11-2175&volume=18&issue=8&pages=2290-300&publication_year=2012&author=Llovet%2CJM&author=Pe%C3%B1a%2CCEA&author=Lathia%2CCD
• What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25512453 each month?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Assessment%20of%20liver%20function%20in%20patients%20with%20hepatocellular%20carcinoma%3A%20a%20new%20evidence-based%20approach-the%20ALBI%20grade&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2014.57.9151&volume=33&issue=6&pages=550-8&publication_year=2015&author=Johnson%2CPJ&author=Berhane%2CS&author=Kagebayashi%2CC
• How much profit does https://link.springer.com/doi/10.1007/s10637-015-0292-9 make?
• Financial intake of https://link.springer.com/article/10.1007/s11523-017-0484-7/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1yltbrF
• Find out how much http://scholar.google.com/scholar_lookup?&title=Liver%20function%20assessment%20according%20to%20the%20albumin-bilirubin%20%28ALBI%29%20grade%20in%20sorafenib-treated%20patients%20with%20advanced%20hepatocellular%20carcinoma&journal=Investig%20New%20Drugs&doi=10.1007%2Fs10637-015-0292-9&volume=33&issue=6&pages=1257-62&publication_year=2015&author=Ogasawara%2CS&author=Chiba%2CT&author=Ooka%2CY earns monthly
• https://citation-needed.springer.com/v2/references/10.1007/s11523-017-0484-7?format=refman&flavour=references's financial summary
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/search?sortBy=newestFirst&dc.creator=Gillian%20M.%20Keating make?
• How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gillian%20M.%20Keating generate?
• What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gillian%20M.%20Keating%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much income is https://link.springer.com/article/10.1007/s11523-017-0484-7/mailto:[email protected] earning monthly?
• Learn how profitable https://s100.copyright.com/AppDispatchServlet?title=Sorafenib%3A%20A%20Review%20in%20Hepatocellular%20Carcinoma&author=Gillian%20M.%20Keating&contentID=10.1007%2Fs11523-017-0484-7©right=Springer%20International%20Publishing%20Switzerland&publication=1776-2596&publicationDate=2017-03-15&publisherName=SpringerNature&orderBeanReset=true is on a monthly basis
• How profitable is https://crossmark.crossref.org/dialog/?doi=10.1007/s11523-017-0484-7?
• How much profit does https://citation-needed.springer.com/v2/references/10.1007/s11523-017-0484-7?format=refman&flavour=citation make?
• Learn about the earnings of https://link.springer.com/article/10.1007/s11523-017-0484-7/search?query=Overall%20Survival&facet-discipline="Medicine%20%26%20Public%20Health"
• How much profit does https://link.springer.com/article/10.1007/s11523-017-0484-7/search?query=Sorafenib&facet-discipline="Medicine%20%26%20Public%20Health" make?
• Find out how much https://link.springer.com/article/10.1007/s11523-017-0484-7/search?query=Tace&facet-discipline="Medicine%20%26%20Public%20Health" earns monthly
• How much does https://link.springer.com/article/10.1007/s11523-017-0484-7/search?query=Median%20Overall%20Survival&facet-discipline="Medicine%20%26%20Public%20Health" earn?
• https://link.springer.com/article/10.1007/s11523-017-0484-7/search?query=National%20Comprehensive%20Cancer%20Network&facet-discipline="Medicine%20%26%20Public%20Health"'s financial summary
• https://link.springer.com/journals/a/1's financial summary
• How much does https://link.springer.com/books/a/1 net monthly?
• How much revenue does https://link.springer.com/journals produce monthly?
• Income figures for https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral
• What's the monthly income of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
• How much income is https://www.springernature.com/gp/products earning monthly?
• How much does https://www.springernature.com/gp/librarians generate monthly?
• How much does https://www.springernature.com/gp/societies pull in monthly?
• How much does https://www.springernature.com/gp/partners net monthly?
• What's the total monthly financial gain of https://www.springer.com/?
• What's the revenue for https://www.nature.com/?
• What's the financial gain of https://www.biomedcentral.com/?
• What is the earnings of https://www.palgrave.com/?
• What's the total monthly financial gain of https://www.apress.com/?
• What's the total monthly financial gain of https://link.springer.com/brands/discover?
• How much does https://www.springernature.com/gp/legal/ccpa gross monthly?
• See how much https://www.springernature.com/gp/info/accessibility makes per month
• How much income is https://link.springer.com/termsandconditions earning monthly?
• How much does https://support.springernature.com/en/support/home pull in?
• Get to know https://link.springer.com/legal-notice's earnings
• How much profit is https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations making per month?
• How much does https://www.springernature.com/ pull in monthly?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

Emails and Hosting {✉️}

Mail Servers:

• mx.zoho.eu
• mx2.zoho.eu
• mx3.zoho.eu

Name Servers:

• josh.ns.cloudflare.com
• zita.ns.cloudflare.com

CDN Services {📦}

• Crossref